[Free Online Symposium] Advances in Immuno-Oncology (jointly by PBSS and BioScience Forum)
Speakers:
Organizers: Toby Freedman, Joseph Carlino, Shichang Miao, Snow Ge, Wenfeng Xu, Donald McCarthy and Betty Chang
Date: 2021-08-11- 08/12/2021
Time: 8:30-13:00 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2021-08-10 (it will close sooner if the seating cap is reached)
About the Topic
The last few years have seen major advancements in cancer treatment through immunotherapy. This symposium aims to provide a comprehensive overview of the emerging concepts in cancer immunotherapy from the latest biologic insights in academia and the latest clinical data for approved and investigational immuno-oncology agents from key biotech and pharmaceutical companies. We will discuss the latest partnership trends and business development efforts in this rapidly evolving landscape.
Tentative Agenda:
Day 1, Wednesday, August 11, 2021 (Pacific Time)
8:30 AM – 8:45 AM Welcome Remarks (Shichang Miao, President of PBSS & Joseph Carlino, President of BioScience Forum)
8:45 AM – 9:20 AM Targeting MYC Oncogene Pathway: Global Gatekeeper of Tumor Growth and Immune Evasion (Dean Felsher, Professor, Stanford Medical School)
9:20 AM – 9:55 AM Engineering IL-12 for Localized Tumoral Activity (Jeff Hubbell, Scientific Founder, Arrow Immune)
9:55 AM – 10:30 AM Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment (Elsa Quintana, Director and Head of Immuno-Oncology, Revolution Medicines)
10:30 AM – 10:40 AM Major Sponsor presentation
10:40 AM – 10:50 AM BREAK
10:50 AM – 11:25 AM A novel platform for localized intratumoral expression of immunotherapy: GET IT (Bridget O’Keeffe, VP – Clinical Development, OncoSec)
11:25 AM – 12:00 PM Tumor-targeting immune stimulating antibody conjugates (David Dornan, Chief Scientific Officer, Bolt Biotherapeutics)
12:00 PM – 12:35 PM T-cell dependent bispecific molecules (Vittal Shivva, Principal Scientist, Genentech)
12:35 PM – 1:10 PM How does PD-1 immunotherapy work — mechanistic insights from recent studies? (Adil Daud, Professor, UCSF)
1:10 PM – 1:40 PM Panel Discussion (All speakers; Moderated by Donald McCarthy of PBSS)
Day 2, Thursday, August 12, 2021 (Pacific Time)
8:30 AM – 8:35 AM Welcome Remarks (Toby Freedman, BioScience Forum)
8:35 AM – 9:10 AM IL-1RAP mAb (Goran Forsberg, CEO, Cantargia)
9:10 AM – 9:45 AM Elucidating the anti-cancer activity of adenosine inhibition: A2R blockade (etrumadenant) and CD73 inhibition (AB680) in clinical trials (Juan Jaen, President/Head of R&D, Arcus BioSciences)
9:45 AM – 10:20 AM Novel Myeloid Checkpoint Inhibitors as Next Generation of Immune-Oncology Therapy (An Song, Chief Scientific Officer, Immune-Onc)
10:20 AM – 10:55 AM Targeting HLA-G-Mediated Immunosuppression with a First-in-Class Antagonist Antibody (Courtney Beers, Chief Scientific Officer, Tizona Therapeutics)
10:55 AM – 11:05 AM Break
11:05 AM – 11:40 AM A survey of the PD-1 / PD-L1 small molecule inhibitors landscape (Penglie Zhang, VP – Chemistry, ChemoCentryx)
11:40 AM – 12:15 PM Mesoscale Engineered Molecules (MEMs) Enable Identification of Privileged Epitopes to Enhance Potent Antibody Dependent Cellular Cytotoxicity of an anti-CD25 Treg Depleting Antibody (Ramesh Balgia,Chief Scientific Officer, RubrYc Therapeutics)
12:15 PM – 12:50 PM Addressing Relapse in Liquid Tumors: Reversing Antigen Escape with Bryostatin-1 (Sam Kongsamut, VP – Research, BryoLogyx)
12:50 PM – 1:25 PM The Amazing Race of I/O Agents: Business Development landscape for immuno-oncology (Cheni Kwok, Linear Dreams & Ji Li, VP, Immune-Onc)
1:25 PM – 1:55 PM Panel Discussion (All speakers; Moderated by Betty Chang & Wenfeng Xu of PBSS)
Event Information
Event Topic:
Advances in Immuno-Oncology
Event Description:
Date/Time:
Date(s) - 08/11/21 - 08/12/21
8:30 am - 12:30 pm
Event Location:
Other:
Event Details
Event Type